*Assessed by independent central review in the ITT population. The OS improvement in the primary analysis population (median OS: 12.1 months vs 6.7 months; HR: 0.48; P<.0001) was consistent with the ITT population. The primary analysis population consisted of patients without present or prior history of brain metastases at baseline (n=468). The ITT population consisted of patients with or without brain metastases at baseline (N=529). ITT population final database lock 25 February 2021. ^1†TRODELVY demonstrated a 49% reduction in the risk of death.¹